US OptionsDetailed Quotes

MGNX241220P7500

Watchlist

3.40
0.000.00%

15min DelayClose Dec 20 15:57 ET

0.00High0.00Low

Macrogenics Stock Discussion

Trytosaveabit

Nov 5 18:30

Allow me to break it down! This is what most will see tomorrow! Well the broad strokes anyways! Hehehe

$Macrogenics (MGNX.US)$ Financial Performance:
MacroGenics reported a significant increase in Q2 2024 revenue of $110.7 million, compared to $10.4 million in the same quarter the previous year.
Net income for the quarter was $56.3 million, significantly higher than the $17.6 million recorded in Q3 2023.
The financial improvements were largely due to a $100 million milestone payment from Incyte, a...

Trytosaveabit

Nov 5 15:18

New 8K ( earning & updates )

$Macrogenics (MGNX.US)$ Any that are interested! I advise reading Doc 2 in that new 8K! Could be a very interesting upcoming catalyst before EOY! Hehehe

Trytosaveabit

Nov 5 15:02

Nice

$Macrogenics (MGNX.US)$ Reuters· just
MacroGenics Q3 Net Income USD 56.3 Million Vs. IBES Estimate USD 11.2 Million

Jaguar8

Nov 5 15:02

NEWS ER

$Macrogenics (MGNX.US)$
Positive
▪️Revenue increased significantly to $110.7M from $10.4M YoY
▪️Net income grew to $56.3M from $17.6M YoY
▪️Strong cash position of $200.4M
▪️Secured $100M milestone payment from Incyte
▪️Pending MARGENZA sale for $40M upfront plus up to $35M in milestones
Negative
▪️R&D expenses increased to $40.5M from $30.1M YoY
▪️SG&A expenses rose to $14.1M from $12.4M YoY
▪️Paused development efforts in alternative tumor types for vobra duo

Teddy123

Oct 22 06:37

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®

$Macrogenics (MGNX.US)$
22/10/2024 - 19:30
ROCKVILLE, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)-- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, and TerSera Therapeutics LLC, a privately-held biopharmaceutical company with a focus in oncology and non-opioid pain ma...

Stock_Drift

Sep 15 04:34

They want LESS to be better. No Moomoo research doctors are allowed to comment without a minimum of 2000 peer reviewed research hours. And that’s a low # if you know.

$Macrogenics (MGNX.US)$

SpeedUp21

Sep 15 02:42

$Macrogenics (MGNX.US)$ get up and let's go..

Jaguar8

Sep 15 02:39

WEEKEND NEWS

$Macrogenics (MGNX.US)$
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
MacroGenics (NASDAQ: MGNX) presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine(vobra duo) for metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024.
Key findings include:
▪️6-month radiographic progression-free survival (rPFS) rate: 69% for 2.0 mg...

Jaguar8

Sep 8 18:11

NEWS

$Macrogenics (MGNX.US)$
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
MacroGenics (NASDAQ: MGNX) announced a poster presentation of Phase 2 data for vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024. The TAMARACK trial results will be presented on September 15, 2024, featuring updated safety and efficacy data, including the primary endpoint of 6-month radiographic progression-free survival (rPFS).
Th...

103622690 DK

Aug 2 06:55

$Macrogenics (MGNX.US)$
f@#$%^&* up

No comment yet